Navigation Links
Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
Date:3/6/2008

rding the approval of Renvela(R) for use in non-dialysis chronic kidney disease patients and the timing of such discussions; the availability and extent of third-party reimbursement for Renvela(R); and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise these statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Genzyme(R), Renagel(R) and Renvela(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Media Contact: Investor Contact:

Erin Emlock Patrick Flanigan

(617) 768-6923 (617) 768-6563


'/>"/>
SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
2. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
3. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
4. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
5. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
6. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
7. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
8. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
9. Genzyme Launches Cholestagel(R) in Europe
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... PAREXEL International Corporation (Nasdaq: PRXL ) will ... January 31, 2011 after the close of the stock market. ... www.PAREXEL.com and on the PR Newswire website at ... and live webcast at 10:00 a.m. EST on Tuesday, February ...
... 2011 Advanced Pain Remedies (APR), a subsidiary of ... has been received, to advance its lead development candidate, ... targeting of specific cell types to manipulate them for ... million grant from the National Cancer Institute (NCI). Advanced ...
... CITY, Kan., Jan. 7, 2011 Aratana Therapeutics, a newly-formed ... animal health industry, today announced that it has closed a ... Avalon Ventures. "At Aratana, we will be focused ... them in new ways to treat and care for animals," ...
Cached Biology Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call 2Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 2Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 3
(Date:7/10/2014)... in the West African nation Burkina Faso today ... Sayana Press has the potential to increase access ... system and in communities by combining a lower-dose ... medroxyprogesterone acetate)with the BD Uniject injection system. , ... countries expected to begin introducing Sayana Press in ...
(Date:7/9/2014)... healthy women differ from bacteria in women with ... from Loyola University Chicago Stritch School of Medicine. ... in the American Society for Microbiology,s online journal ... play a role in female urinary health. , ... poorly understood, condition with symptoms similar to urinary ...
(Date:7/9/2014)... Cancer Research Centre (CNIO) have discovered that NANOG, an ... division in stratified epitheliathose that form part of the ... the vaginain adult organisms. According to the conclusions of ... , this factor could also play a role in ... the oesophagus and skin. , The pluripotency factor NANOG ...
Breaking Biology News(10 mins):Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2
... the limits of life in extreme environments, scientists have discovered ... an Antarctic lake sealed under more than 65 feet of ... the Proceedings of the National Academy of Sciences , ... been isolated from the surface environment -- and external sources ...
... Johns Hopkins researchers report concrete steps in the use of ... drugs. Their success highlights a pathway toward faster, cheaper drug ... to pre-test a therapy,s safety and effectiveness on cultured clones ... in an article published November 25 on the website of ...
... the first time that marine algae can be just as ... scientists genetically engineered marine algae to produce five different kinds ... used could be employed to enhance the yield of petroleum-like ... in a paper published online in the current issue of ...
Cached Biology News:UIC scientists find ancient microbes in salty, ice-sealed Antarctic lake 2Study advances use of stem cells in personalized medicine 2Bioengineered marine algae expands environments where biofuels can be produced 2